COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00193518
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : May 3, 2011
CTI BioPharma
Information provided by:
SCRI Development Innovations, LLC

Brief Summary:
Additional active agents are needed to further improve the treatment of patients with CLL/SLL. Increasing information exists regarding the activity of arsenic trioxide in other hematologic malignancies. Since arsenic trioxide produces mild to moderate myelosuppression and is not as immunosuppressive as other available agents, it may be an additional treatment option for CLL/SLL. This study will evaluate the feasibility and toxicity of arsenic trioxide in patients with relapsed or refractory CLL/SLL

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Drug: Arsenic Trioxide Phase 2

Detailed Description:

Upon determination of eligibility, patients will receive:

  • Arsenic Trioxide

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 41 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial Of Arsenic Trioxide (TRISENOX) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Study Start Date : April 2004
Actual Primary Completion Date : April 2006
Actual Study Completion Date : April 2006

Primary Outcome Measures :
  1. Overall response rate

Secondary Outcome Measures :
  1. Progression-free survival
  2. Toxicity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

To be included in this study, you must meet the following criteria:

  • Histologically proven B-cell CLL/SLL.
  • Must have had a minimum of 1 and a maximum of 3 previous systemic regimens
  • Must have progressive CLL/SLL
  • Measurable or evaluable disease
  • ECOG performance status 0, 1, or 2
  • Age > 18 years.
  • Patients with cytopenias caused by bone marrow involvement are eligible
  • All patients must give written informed consent prior to entering this study.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

  • Unstable active infection on the basis of neutropenia
  • Previous severe opportunistic infections
  • Severe immune mediated anemia or thrombocytopenia
  • Serious underlying medical conditions
  • Brain metastases or meningeal involvement
  • History of other neoplasms
  • Significant underlying heart dysfunction
  • Women who are pregnant or

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00193518

Layout table for location information
United States, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37023
Sponsors and Collaborators
SCRI Development Innovations, LLC
CTI BioPharma
Layout table for investigator information
Principal Investigator: John D. Hainsworth, MD SCRI Development Innovations, LLC
Layout table for additonal information
Responsible Party: SCRI Oncology Research Consortium, SCRI Identifier: NCT00193518    
Other Study ID Numbers: SCRI LYM 33
First Posted: September 19, 2005    Key Record Dates
Last Update Posted: May 3, 2011
Last Verified: May 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Arsenic Trioxide
Antineoplastic Agents